Outset Medical, Inc. Common Stock
OMOutset Medical, Inc. is a healthcare technology company that develops and commercializes innovative dialysis solutions. Its flagship product, the Tablo Hemodialysis System, aims to simplify the delivery of dialysis treatment by integrating multiple functions into a compact, user-friendly device, improving access and efficiency for dialysis clinics and patients.
Company News
U.S. stock futures fell on Tuesday after the Senate passed a resolution to reopen the government. Market attention was focused on several company earnings reports and potential Federal Reserve interest rate cuts.
Outset Medical, a medical technology company, announced that members of its management team will participate in the RBC Capital Markets Global Health Care conference on May 20, 2025. The company's Tablo Hemodialysis System, which is FDA-cleared for use from the hospital to the home, represents a significant technological advancement in the dialys...
Outset Medical, a medical technology company, announced a one-for-fifteen reverse stock split. The company also plans to release its Q1 2025 financial results and host a conference call to discuss the results.
Outset Medical reported strong Q4 earnings, with revenue and adjusted EPS beating analyst estimates. The company saw improved gross margins and reduced operating expenses, signaling progress towards profitability. Outset remains optimistic about future growth, projecting revenue of $115-$125 million by 2025.
Kuehn Law is investigating Outset Medical, Inc. (OM) for potential breach of fiduciary duties, alleging the company misrepresented or failed to disclose information about its Tablo products and their regulatory approval status.
